Health Catalyst (NASDAQ:HCAT) Given New $21.00 Price Target at BTIG Research
Health Catalyst (NASDAQ:HCAT) Given New $21.00 Price Target at BTIG Research
Health Catalyst (NASDAQ:HCAT – Get Rating) had its target price trimmed by BTIG Research from $25.00 to $21.00 in a report published on Monday morning, The Fly reports. The brokerage currently has a buy rating on the stock.
據The Fly報道,BTIG Research週一上午發佈的一份報告將Health Catalyst(納斯達克:HCAT-GET評級)的目標價從25.00美元下調至21.00美元。該經紀公司目前對該股的評級為買入。
Several other brokerages have also weighed in on HCAT. Piper Sandler lowered shares of Health Catalyst from an overweight rating to a neutral rating and dropped their price objective for the company from $21.00 to $11.00 in a research report on Tuesday, September 13th. KeyCorp assumed coverage on shares of Health Catalyst in a research report on Thursday, September 15th. They issued a sector weight rating on the stock. The Goldman Sachs Group dropped their price objective on shares of Health Catalyst from $29.00 to $18.00 and set a buy rating on the stock in a research report on Wednesday, August 10th. Stifel Nicolaus lowered shares of Health Catalyst from a buy rating to a hold rating and dropped their price objective for the company from $27.00 to $16.00 in a research report on Friday, August 5th. Finally, JPMorgan Chase & Co. lowered shares of Health Catalyst from an overweight rating to a neutral rating and dropped their price objective for the company from $20.00 to $16.00 in a research report on Friday, August 5th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Health Catalyst presently has a consensus rating of Moderate Buy and an average price target of $25.62.
其他幾家券商也加入了HCAT的行列。在9月13日星期二的一份研究報告中,派珀·桑德勒將Health Catalyst的股票評級從增持下調至中性,並將該公司的目標價從21.00美元下調至11.00美元。KeyCorp在9月15日星期四的一份研究報告中對Health Catalyst的股票進行了報道。他們對該股發佈了行業權重評級。8月10日,週三,高盛夫婦在一份研究報告中將Health Catalyst的股票目標價從29.00美元下調至18.00美元,並對該股設定了買入評級。在8月5日星期五的一份研究報告中,Stifel Nicolaus將Health Catalyst的股票評級從買入下調至持有評級,並將該公司的目標價從27.00美元下調至16.00美元。最後,在8月5日星期五的一份研究報告中,摩根大通將Health Catalyst的股票評級從增持下調至中性,並將該公司的目標價從20.00美元下調至16.00美元。4名股票研究分析師對該股的評級為持有,8名分析師給予買入評級,一名分析師給予該公司強烈的買入評級。根據MarketBeat的數據,Health Catalyst目前的共識評級為中等買入,平均目標價為25.62美元。
Health Catalyst Trading Up 3.3 %
Health Catalyst交易上漲3.3%
NASDAQ HCAT opened at $9.65 on Monday. The firm's fifty day moving average price is $12.83 and its two-hundred day moving average price is $16.29. Health Catalyst has a 1 year low of $9.03 and a 1 year high of $54.27. The firm has a market capitalization of $528.08 million, a P/E ratio of -3.30 and a beta of 1.23.
納斯達克HCAT週一開盤報9.65美元。該公司的50日移動均線價格為12.83美元,200日移動均線價格為16.29美元。Health Catalyst的一年低點為9.03美元,一年高位為54.27美元。該公司市值為5.2808億美元,市盈率為-3.30,貝塔係數為1.23。
Insiders Place Their Bets
內部人士下注
In other news, Director Duncan Gallagher acquired 8,400 shares of Health Catalyst stock in a transaction on Thursday, August 18th. The shares were purchased at an average cost of $11.69 per share, for a total transaction of $98,196.00. Following the completion of the purchase, the director now directly owns 28,805 shares of the company's stock, valued at approximately $336,730.45. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 1,964 shares of company stock worth $26,306 over the last ninety days. Corporate insiders own 1.50% of the company's stock.
在其他新聞方面,董事鄧肯·加拉格爾在8月18日(星期四)的一筆交易中收購了8,400股Health Catalyst股票。這些股票是以每股11.69美元的平均成本購買的,總交易額為98,196.00美元。收購完成後,董事現在直接持有該公司28,805股股票,價值約336,730.45美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過這個環節。在過去的90天裏,內部人士已經出售了1,964股公司股票,價值26,306美元。企業內部人士持有該公司1.50%的股份。
Institutional Investors Weigh In On Health Catalyst
機構投資者看好Health Catalyst
A number of large investors have recently bought and sold shares of HCAT. Fairfield Bush & CO. bought a new position in shares of Health Catalyst in the first quarter worth about $25,000. Macquarie Group Ltd. bought a new position in shares of Health Catalyst in the second quarter worth about $26,000. Manchester Capital Management LLC lifted its holdings in shares of Health Catalyst by 667.5% in the first quarter. Manchester Capital Management LLC now owns 1,159 shares of the company's stock worth $30,000 after acquiring an additional 1,008 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Health Catalyst in the first quarter worth about $33,000. Finally, Hardy Reed LLC bought a new position in shares of Health Catalyst in the first quarter worth about $80,000. 96.58% of the stock is currently owned by institutional investors and hedge funds.
一些大型投資者最近買賣了HCAT的股票。費爾菲爾德·布什公司在第一季度購買了Health Catalyst的新頭寸,價值約2.5萬美元。麥格理集團(Macquarie Group Ltd.)在第二季度增持了Health Catalyst股票,價值約2.6萬美元。曼徹斯特資本管理公司在第一季度增持了667.5%的Health Catalyst股票。曼徹斯特資本管理有限責任公司在上個季度增持了1,008股後,現在擁有1,159股該公司股票,價值3萬美元。Point72 Hong Kong Ltd在第一季度購買了Health Catalyst的新頭寸,價值約33,000美元。最後,Hardy Reed LLC在第一季度購買了Health Catalyst的新頭寸,價值約8萬美元。96.58%的股票目前由機構投資者和對衝基金持有。
Health Catalyst Company Profile
Health Catalyst公司簡介
(Get Rating)
(獲取評級)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.
Health Catalyst,Inc.為醫療保健組織提供數據和分析技術和服務。其產品包括數據和分析平臺,這是一個面向醫療保健部門的商業級數據和分析平臺;人工智能和數據科學,提供將人工智能集成到現有商業智能工具中,提高分析準確性;人口健康管理,確定整個醫療連續體系的改善,以及成功和自動化工作流的可行指導;金融轉型,提供成本計算和勞動生產率洞察和收入獲取;使用臨牀質量和患者安全數據、分析和專家服務來改進質量和安全;以及國家數據生態系統,用於思想領先和相互知識交流,以通過下一代洞察來轉變醫療交付。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- Is the Market Overreacting with Shopify Stock?
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
- 免費獲取StockNews.com關於Health Catalyst(HCAT)的研究報告
- MarketBeat Podcast,3只股票關注紐蒙特礦業、沃爾瑪、AMC
- Mo Money:奧馳亞集團股價為何上漲
- 市場是否對Shopify Stock反應過度?
- 美聯儲加息:3只股票關注紐蒙特礦業、沃爾瑪、AMC
- 三隻可能在第四季度表現優異的消費類股
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
接受每日健康催化劑的新聞和評級-在下面輸入您的電子郵件地址,以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Health Catalyst和相關公司的最新新聞和分析師評級的每日簡要摘要。